Zusammenfassung
Der Dünndarm besitzt zahlreiche hormonale und metabolische Funktionen, für die neben den Enterozyten enteroendokrine Zellen in der Mukosa verantwortlich sind. So führt eine Freisetzung von Cholezystokinin zu einer Sekretion von Pankreasenzymen und einer Gallenblasenkontraktion. Kürzlich wurde eine hormonelle Regulierung der Gallenblasenfüllung durch das Hormon FGF-15/19 beschrieben, das vermittelt durch Gallensalze aus Enterozyten des terminalen Ileums sezerniert wird und daneben eine Verminderung der Gallensäure- und Fettsäuresynthese sowie eine Hemmung der Glukoneogenese bewirkt. Mit Ghrelin ist ein intestinales Hormon bekannt, das die Nahrungsaufnahme steigert. Dem stehen eine Reihe von Sättigungshormonen wie z. B. Cholezystokinin und Glucagon-like Peptide gegenüber, durch deren Wirkung die Nahrungsaufnahme gehemmt wird. Die Kenntnis dieser Hormone und ihrer Funktionen ist für das Verständnis der Stoffwechselkontrolle und der Pathophysiologie zahlreicher Erkrankungen wesentlich. Hieraus ergeben sich pharmakologische Ansätze z. B. zur Behandlung von Motilitätsstörungen, des Diabetes mellitus Typ 2, der nicht-alkoholischen Fettlebererkrankung und der Adipositas.
Abstract
The small intestine exhibits numerous hormonal and metabolic functions. These are mediated by enteroendocrine cells that are expressed in addition to enterocytes in the mucosa of the small intestine. The release of cholecystokinin causes the secretion of pancreatic enzymes and a contraction of the gallbladder. Recently, a hormonal regulation of gallbladder filling was confirmed. This is mediated by the hormone FGF15/19 which is secreted by enterocytes of the terminal ileum following induction of its expression by bile acids. In addition, FGF15/19 reduces synthesis of bile acids and fatty acids and inhibits gluconeogenesis. Ghrelin is the only intestinal hormone that increases food intake. Contrary, a number of hormones such as cholecystokinin and glucagon-like peptide are expressed in the small intestine and mediate satiation. Knowledge of the intestinal hormones and their functions is important for the full understanding of metabolic control and provides targets for innovative therapy of several diseases such as diabetes type 2, non-alcoholic steatohepatitis and obesity.
Abbreviations
- cAMP:
-
Zyklisches Adenosinmonophosphat
- CCK:
-
Cholezystokinin
- CYP7A1:
-
Cholesterin-7α-Hydroxylase
- DPP-IV:
-
Dipeptidylpeptidase IV
- FXR:
-
Farnesol-X-Rezeptor
- FGF:
-
Fibroblast Growth Factor
- FGFR:
-
Fibroblast Growth Factor Receptor
- FOXO-1:
-
Forkhead Transcription Factor 1
- GLP:
-
Glucagon-like Peptide
- IgA:
-
Immunglobulin A
- mRNA:
-
Messenger-Ribonukleinsäure
- NPY:
-
Neuropeptide Y
- PYY:
-
Peptide Tyrosine Tyrosine
- SHP-1:
-
Small Heterodimer Partner 1
- VIP:
-
Vasoaktives intestinales Peptid
- ZNS:
-
Zentrales Nervensystem
Literatur
Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131–2157
Bhatnagar S, Damron HA, Hillgartner FB (2009) Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 284: 10023–10033
Choi M, Moschetta A, Bookout al. et al. (2006) Identification of a hormonal basis for gallbladder filling. Nat Med 12: 1253–1255
Crawley JN, Beinfeld MC (1983) Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302: 703–706
Cummings DE, Overduin J (2007) Gastrointestinal regulation of food intake. J Clin Invest 117: 13–23
Cummings DE, Weigle DS, Frayo RS et al. (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346: 1623–1630
Dueland S, Reichen J, Everson GT et al. (1991) Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem J 280: 373–377
Fu L, John LM, Adams SH et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594–2603
Giralt M, Vergara P (1999) Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Dig Dis Sci 44: 322–329
Grider JR (1994) Role of cholecystokinin in the regulation of gastrointestinal motility. J Nutr 124: 1334S–1339S
Inagaki T, Choi M, Moschetta A et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217–225
Kissileff HR, Carretta JC, Geliebter A et al. (2003) Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol 285: R992–998
Masclee AA, Vu MK (2003) Gallbladder motility in inflammatory bowel diseases. Dig Liver Dis 35 (Suppl 3): S35–38
Moran TH, Kinzig KP (2004) Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol 286: G183–188
Moschetta A, Stolk MF, Rehfeld JF et al. (2001) Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 15: 181–185
Murphy KG, Dhillo WS, Bloom SR (2006) Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 27: 719–727
Pandak WM, Heuman DM, Hylemon PB et al. (1995) Failure of intravenous infusion of taurocholate to down-regulate cholesterol 7 alpha-hydroxylase in rats with biliary fistulas. Gastroenterology 108: 533–544
Pironi L, Stanghellini V, Miglioli M et al. (1993) Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology 105: 733–739
Qualmann C, Nauck MA, Holst JJ et al. (1995) Glucagon-like peptide 1 (7–36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 30: 892–896
Schaap FG, Gaag NA van der, Gouma DJ et al. (2009) High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49: 1228–1235
Schreuder TC, Marsman HA, Lenicek M et al. (2010 The hepatic response to FGF19 is impaired in patients with non-alcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 298: G440–445
Shaffer EA (2000) Review article: control of gall-bladder motor function. Aliment Pharmacol Ther 14 (Suppl 2): 2–8
Shaffer EA (2006) Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 20: 981–996
Shin DJ, Osborne TF (2009) FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 284: 11110–11120
Strader AD, Woods SC (2005) Gastrointestinal hormones and food intake. Gastroenterology 128: 175–191
Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407: 908–913
Vincent RP, le Roux CW (2008) The satiety hormone peptide YY as a regulator of appetite. J Clin Pathol 61: 548–552
Wang PY, Caspi L, Lam CK et al. (2008) Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452: 1012–1016
Wren AM, Seal LJ, Cohen MA et al. (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86: 5992
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wittenburg, H., Tennert, U. & Mössner, J. Hormonale und metabolische Funktionen des Dünndarms. Internist 51, 695–701 (2010). https://doi.org/10.1007/s00108-009-2564-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-009-2564-y